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Background: Candesartan cilexetil has been shown to effectively reduce blood pressure and 
cardiovascular risk. Whether it is advantageous to combine candesartan cilexetil with low-dose 
hydrochlorothiazide (HCTZ) or uptitrate it in cases of insufficient blood pressure control has 
not been fully investigated under routine clinical conditions.
Methods: CHILI Triple T is a prospective, noninterventional, observational study. Patients 
with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination 
of candesartan cilexetil 16 mg and HCTZ 12.5 mg (combination therapy group) or high-dose 
monotherapy with candesartan cilexetil 32 mg (high-dose monotherapy group).
Results: A total of 4600 patients with a mean age of 63.1 ± 11.0 years, of which 44.7% were 
female, was included. The combination therapy group had 3337 patients, and the high-dose 
monotherapy group 1263 patients. Patients in both treatment groups were c  omparable with 
respect to age and gender, but patients receiving high-dose monotherapy had a slightly higher 
mean systolic blood pressure, more prior revascularizations, renal insufficiency, diabetic 
n  ephropathy, peripheral artery disease, and a lower ankle brachial index. The use of c  ombination 
therapy resulted in a blood pressure reduction of −28.5 ± 13.8/−14.2 ± 9.4 mm Hg (P , 0.001 
vs 160.2 ± 13.3/94.5 ± 8.2 mm Hg at baseline). The use of high-dose m  onotherapy reduced 
blood pressure by −29.73 ± 15.3/−14.1 ± 9.6 mm Hg (P , 0.001 vs 162.4 ± 14.7/94.7 ± 8.7 mm 
Hg at baseline). Differences in subgroups of patients defined by age, gender, body mass 
index, dyslipidemia, waist circumference, s  moking, prior c  ardiovascular event, glomerular 
fi  ltration rate, and microalbuminuria were minor, although partially significant. Tolerability 
was   excellent, with only 28 out of 3358 patients (0.8%) in the combination therapy group and 
15 out of 1273 patients (1.2%) in the high-dose m  onotherapy group experiencing any adverse 
event, of which one in each group was considered to be serious (,0.1%).
Conclusions: Both the fixed-dose combination of candesartan cilexetil 16 mg and HCTZ 
12.5 mg and high-dose monotherapy with candesartan 32 mg were highly effective in lowering 
blood pressure in patients at increased cardiovascular risk. Tolerability was excellent. The choice 
of either strategy therefore largely depends on the principal aim: blood pressure reduction with 
pronounced volume restriction or pronounced additional end-organ protection.
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Background
Angiotensin receptor blockers (ARBs) are highly   effective at 
reducing blood pressure in patients with arterial   hypertension 
and have shown to protect against end-organ damage. 
C  andesartan cilexetil is an ARB that has been shown to provide 
effective blood pressure reduction alone1–4 or in combination 
with hydrochlorothiazide (HCTZ).5–7 Its p  articular benefit, how-
ever, is related not only to its blood   pressure-lowering effect but 
more to its protective effect on end-organs such as the heart,8–11 
kidneys,12–16 and brain.17,18 This has usually been achieved in 
doses up to 32 mg of   candesartan cilexetil and is thought to be 
mediated by effects beyond blood pressure control.19
ARBs, including candesartan cilexetil, are frequently 
used as first-line monotherapy because of their high efficacy, 
tolerability, and patient compliance. ARB treatment is also 
an option in patients previously receiving antihypertensive 
monotherapy with angiotensin-converting enzyme (ACE) 
inhibitors, β-blockers, or calcium channel blockers, because 
patients can be safely switched, which results in additional 
blood pressure lowering.20 When blood pressure control at 
low ARB doses is not sufficient, either ARB doses may be 
increased or combination therapy initiated early.21 There is, 
however, no recommendation on the decision to either com-
bine or increase dose, and reports on clinical experience from 
primary care are sparse.
We therefore designed a noninterventional study in 
p  rimary care practice asking physicians to document 
patients at increased cardiovascular risk who had either been 
p  rescribed a fixed-dose combination of candesartan cilexetil 
16 mg/HCTZ 12.5 mg or a high-dose monotherapy with 
candesartan 32 mg because blood pressure control under 
previous antihypertensive pharmacotherapy was insufficient. 
We chose a noninterventional design to cover the broadest 
possible patient spectrum and because results of these s  tudies 
are directly applicable to clinical practice because of the high 
external validity of this study type.
Patients and methods
CHILI Triple T was a noninterventional, noncontrolled, 
open-label study with a 12-week follow-up that was con-
ducted with primary care physicians, internists, or diabetolo-
gists throughout Germany. The study was registered at the 
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) 
and K  assenärztliche Bundesvereinigung (KBV) in accor-
dance with paragraph 67, section 6 of the German Drug Act 
2010. A  pplicable data protection regulations were respected. 
P  articipating physicians received remuneration for the docu-
mentation of patients in a  ccordance with the G  ebührenordnung 
für Ärzte (GOÄ). Ethical approval was obtained prior to   
commencement of the study by the Landesärztekammer 
Thüringen, Jena, Germany, on August 12, 2008. Written 
informed consent was obtained from all patients.
Patients
Patients aged at least 18 years were eligible for inclusion when 
a treatment decision to start candesartan 16 mg and HCTZ 
12.5 mg or candesartan 32 mg due to arterial h  ypertension had 
been made. Further necessary inclusion criteria were u  ncontrolled 
blood pressure ($130/80 mm Hg) on prior a  ntihypertensive ther-
apy for at least 8 weeks, the   presence of additional c  ardiovascular 
risk factors (eg,   diabetes or h  yperlipidemia), and compliance with 
the prescribing i  nformation of Blopress® 16 mg Plus or Blo-
press® 32 mg (both Takeda Pharma GmbH, Aachen, Germany). 
Physicians were allowed to adjust the dose of any concomitant 
medication as necessary.
Objective
The objective of this study was to compare the efficacy 
and safety of a fixed-dose combination treatment strategy 
(  candesartan cilexetil 16 mg and HCTZ 12.5 mg) with 
high-dose monotherapy (candesartan cilexetil 32 mg). 
Treatment s  trategies were to be compared with respect 
to blood pressure target achievement and blood pressure 
achievement in patients with different cardiovascular risks 
at baseline, and to collect data on tolerability and drug 
safety in the respective treatment group.
Variables
Three visits were scheduled throughout a 12-week follow-up. 
At the first visit (enrolment), demographic data, body mass 
index (BMI), cardiovascular risk factors, concomitant dis-
ease conditions, previous or concomitant therapies, and a 
number of laboratory values were documented. At the man-
datory second visit, blood pressure readings, blood glucose, 
antihypertensive pharmacotherapy, and adverse events were 
documented. At the end of the observation, blood pressure, 
antihypertensive treatment, and changes in laboratory values 
were documented. Blood pressure measurements were con-
ducted in agreement with current guidelines after 5 minutes 
of rest. Treatment satisfaction was monitored as the propor-
tion of physicians indicating patients reaching blood pressure 
goal and patients’ compliance with treatment.
statistics
The case report forms were collected by the clinical research 
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report forms were checked for consistency and a subset 
of case report forms verified with the source data (8%). 
Regarding safety, the trial was adequately sized (n = 4600) 
to identify rare adverse events, ie, those that may not have 
been detected in previous clinical studies (incidence 1:1000) 
with a probability of .95%. The statistical analysis was 
p  erformed descriptively and was interpreted in an explor-
ative way. Comparisons were made for a number of vari-
ables and analyzed using descriptive statistics. The number 
of patients is given for each value, and differences were 
calculated in patients with values at baseline and follow-up 
(per protocol). Data were analyzed with SPSS for Windows, 
Version 17.02 (SPSS, Inc., Chicago, IL, USA). The tests 
applied are indicated in the legends of the tables and figures 
in this article.
Results
Between October 2008 and February 2009 a total of 
4600 patients was included (safety population), of which 4527 
were analyzed for efficacy. Patients were stratified into two 
groups according to treatment chosen: 3337 patients received 
candesartan cilexetil 16 mg in a fixed-dose c  ombination 
with 12.5 mg HCTZ (combination therapy group), and 1263 
patients received candesartan cilexetil 32 mg (monotherapy 
group).
Patient and clinical characteristics  
at baseline
Patients had an overall mean age of 63.1 ± 11.0 years, 
44.7% were female, and the mean blood pressure at base-
line was 160.8 ± 13.7/94.6 ± 8.3 mm Hg (office measure-
ments). Although age and gender were comparable between 
groups, there was a statistically significant difference 
with respect to a slightly higher systolic blood pressure 
at baseline, more prior revascularization procedures, 
renal insufficiency,   diabetic nephropathy, peripheral arte-
rial disease, ankle brachial index , 0.9, and pulse wave 
velocity . 12 m/s in patients receiving candesartan cilexetil 
32 mg (Table 1).
Pharmacotherapy at baseline and during follow-up 
is illustrated in Table 2. β-blockers, ACE inhibitors, and 
calcium channel blockers were the most frequently used 
Table 1 Baseline characteristics of the study population (U1)
Variables Candesartan 16 mg +  
hydrochlorothiazide 12.5 mg
Candesartan 32 mg P-value 
combination vs 
monotherapy No. of available  
patient data
%/mean 
± SD
No. of available  
patient data
%/mean 
± SD
Males (%) 1828 54.8 713 56.5 0.288
Age (years) 3328 63.3 ± 11.1 1259 62.8 ± 10.6 0.156
Waist circumference (cm) 2706 102.5 ± 14.0 1002 103.0 ± 15.3 0.388
smokers (%) 729 21.8 276 21.9 0.953
Blood pressure office  
measurement
  systolic (mm Hg) 3336 160 ± 13 1260 162 ± 15 ,0.001
  Diastolic (mm Hg) 3337 94 ± 8 1259 95 ± 9 0.374
Diabetes (%) 240 7.2 92 7.3 0.792
concomitant disease (%)
  coronary artery disease  1296 38.8 505 40.0 0.387
  Myocardial infarction 399 12.0 176 13.9 0.065
  Angina pectoris 753 22.6 309 24.5 0.151
  Prior revascularization 450 13.5 203 16.1 0.018
  Heart failure 700 21.0 278 22.0 0.415
  stroke 167 5.0 63 5.0 0.985
  Renal insufficiency 268 8.0 152 12.0 ,0.001
  Diabetic nephropathy 259 7.8 136 10.8 0.001
  Diabetic retinopathy 235 7.0 98 7.8 0.402
  Peripheral artery disease 406 12.2 187 14.8 0.018
    Prior cardiovascular disease  
in first-grade relatives
1944 58.3 731 57.9 0.868
  iMT . 0.9 mm or plaque 505 70.5 235 69.7 0.083
  ABi , 0.9 212 29.6 131 38.9 ,0.001
  PWV . 12 ms 65 9.1 55 16.3 ,0.001
Abbreviations: ABi, ankle brachial index; iMT, intima media thickness; PWV, pulse wave velocity; sD, standard deviation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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drugs at baseline. Either candesartan cilexetil in mono- or 
combination therapy was added to an existing regimen 
or prior medication was substituted, resulting in 100% 
coverage at baseline. Concomitant drug use was low and 
comparable except for a nominally more frequent use 
of diuretics in the monotherapy group (8.2% vs 2.7%; 
P , 0.001).
Blood pressure reduction
At baseline, patients had comparable blood pressure values 
in both treatment arms and in subgroups, defined by the 
presence of hypertension grade 1–3 (Figure 1). The use of 
combination therapy resulted in a blood pressure reduction 
of −28.5 ± 13.8/−14.2 ± 9.4 mm Hg (P , 0.001 with blood 
pressure of 160.2 ± 13.3/94.5 ± 8.2 mm Hg at baseline). 
Table 2 Pharmacotherapy for the treatment of hypertension at baseline (% of patients)
Candesartan 16 mg +  
hydrochlorothiazide 12.5 mg
Candesartan 32 mg P-value 
combination vs 
monotherapy No. of patients % No. of patients %
Baseline
  Any (of the 5 groups below) 5264 95.8 2206 95.0 0.113
    Angiotensin-converting  
enzyme inhibitors
1613 29.4 642 27.7 0.128
  Angiotensin receptor blockers 425 7.7 217 9.3 0.018
 β -blockers 1561 28.4 636 27.4 0.359
  calcium channel blockers 1049 19.1 424 18.3 0.390
  Diuretics 616 11.2 287 12.4 0.147
candesartan 16 mg/hydrochlorothiazide 12.5 mg 5492 100.0 n.a. n.a. n.a.
candesartan 32 mg n.a. n.a. 2321 100.0 n.a.
concomitant pharmacotherapy
  Any (of the 5 groups below) 659 13.4 435 20.3 ,0.001
  Angiotensin-converting enzyme inhibitors 35 0.7 35 1.6 0.001
  Angiotensin receptor blockers* 46 0.9 18 0.8 0.706
 β -blockers 235 4.8 102 4.8 0.996
  calcium channel blockers 210 4.3 105 4.9 0.228
  Diuretics* 133 2.7 175 8.2 ,0.001
Note: *Other than candesartan 32 mg or candesartan 16 mg and hydrochlorothiazide12.5 mg.
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Figure 1 Blood pressure reduction overall and subgroups with grade 1–3 hypertension (HT) 12 weeks after either candesartan cilexetil/hydrochlorothiazide combination 
(treatment arm 1) or high-dose candesartan monotherapy 32 mg (treatment arm 2). Blood pressure lowering in the total and the subgroups defined by the presence of grade 
1, 2, or 3 hypertension was significant (P , 0.001, pairwise comparison).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The use of high-dose monotherapy reduced blood pressure 
by −29.73 ± 15.3/−14.1 ± 9.6 mm Hg (P , 0.001 with blood 
pressure of 162.4 ± 14.7/94.7 ± 8.7 mm Hg at baseline). 
Differences were highly significant compared with baseline 
(P , 0.0001) and significant for the difference between s  ystolic 
blood pressure values (P = 0.011). Target blood pressure 
achievement (,140/90 mm Hg) was 74.3% in the combination 
therapy group and 70.2% in the monotherapy group.
The treatment-induced blood pressure reduction for 
patient groups, defined by the presence of hypertension 
grade 1–3 (see mean blood pressure readings at baseline in 
the respective subgroups), is illustrated in Figure 1. Blood 
pressure reduction was moderate in grade 1 hypertension 
(−24.1/−12.6 mm Hg combination vs −24.6/−12.5 mm Hg 
monotherapy; both P , 0.0001 vs baseline), increased in 
grade 2 hypertension (−31.2/−15.2 vs −31.4/−14.3; both 
P , 0.0001 vs baseline), and was strongest in patients with 
grade 3 hypertension (−46.6/−21.3 vs −46.5 vs −20.3; both 
P , 0.0001 vs baseline). The correlation (Pearson 0.754) 
between blood pressure at baseline and blood pressure 
reduction was highly significant (P , 0.001); differences 
between mono- and combination therapy were not observed 
(P = n.s.).
Both patient groups had mostly either high or very high 
added risk at baseline, defined by blood pressure readings 
and the presence of comorbid risk factors and disease as 
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Figure 2 cardiovascular risk (%) at baseline and after follow-up according to the european society of Hypertension/european society of cardiology 2007 guidelines.21 
Upper panel: patients receiving candesartan/hydrochlorothiazide; Lower panel: patients receiving candesartan 32 mg. Stratification of cardiovascular risk in five categories. 
Low, moderate, high, and very high added risk refers to 10-year risk of a cardiovascular fatal or nonfatal event.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
90
Bönner et al
outlined in the European Society of Hypertension (ESH)/
European Society of Cardiology (ESC) guidelines (Fig-
ure 2, panel A and B).21 This applied to 44.9% (high) and 
52.9% (very high) of patients with the fixed-dose com-
bination, and to 37.8% (high) and 59.7% (very high) in 
the high-dose monotherapy group. Risk was substantially 
reduced at the 12-week follow-up (P , 0.001 vs baseline 
in both groups); substantially fewer patients had high or 
very high added risk, and more patients had low or moder-
ate added risk. Differences between both treatment groups 
were negligible.
Blood pressure in patient subgroups
The blood pressure reduction in subgroups of patients defined 
by prior or concomitant antihypertensive pharmacotherapy 
is displayed in Table 3. Differences compared with base-
line were significant (P , 0.001), with the least effect 
observed in patients with prior ARB therapy and those with 
  concomitant use of ACE inhibitors. Pronounced effects were 
observed in patients with prior β-blocker or diuretic therapy. 
  Differences between mono- and dual-combination therapy in 
the r  espective subgroups were generally in favor of high-dose 
monotherapy but were significant only for patients for whom 
a β-blocker was withdrawn (P = 0.006).
Blood pressure reductions were further investigated 
in subgroups of patients defined by age, gender, and BMI 
(Figure 3; two panels first row), dyslipidemia, waist circum-
ference, and smoking (Figure 3; two panels second row), and 
prior cardiovascular event, glomerular filtration rate, and the 
presence of microalbuminuria (Figure 3; two panels last row). 
Differences were significant for patients aged #65 years, 
patients with BMI $ 30 kg/m2, patients with dyslipidemia, 
and those who smoke (P , 0.05).
Metabolic parameters and tolerability
Twelve weeks after candesartan cilexetil/HCTZ initiation, 
laboratory values such as glycated hemoglobin, fasting and 
postprandial glucose, lipids, and renal parameters generally 
improved, irrespective of whether mono- or combination   
therapy was employed (Table 4). Differences between treatments 
Table 3 Blood pressure reduction versus baseline with respect to prior and concomitant pharmacotherapy for the treatment of 
hypertension
Candesartan 16 mg +  
hydrochlorothiazide 12.5 mg
Candesartan 32 mg P-value 
∆ combination vs 
∆ monotherapy No. of  
patients
Blood  
pressure  
reduction  
(mm Hg)
P-value vs  
baseline
No. of  
patients
Blood  
pressure  
reduction  
(mm Hg)
P-value vs  
baseline
Prior therapy
  no change of prior therapy 905 28.39 ,0.001 373 29.57 ,0.001 0.166
  change of prior therapy 2395 28.53 ,0.001 865 29.78 ,0.001 0.037
Withdrawn therapy
    Angiotensin-converting  
enzyme inhibitors
1377 28.66 ,0.001 494 30.21 ,0.001 0.046
  Angiotensin receptor blockers 391 25.71 ,0.001 190 26.20 ,0.001 0.681
 β -blockers 327 28.52 ,0.001 130 33.06 ,0.001 0.006
  calcium channel blockers 342 30.33 ,0.001 122 30.34 ,0.001 0.996
  Diuretics 427 30.40 ,0.001 53 32.96 ,0.001 0.259
no. of withdrawn drugs
  1 drug withdrawn 1933 28.22 ,0.001 745 29.29 ,0.001 0.090
 $ 2 drugs withdrawn 468 29.82 ,0.001 121 32.39 ,0.001 0.161
concomitant pharmacotherapy
    Angiotensin-converting  
enzyme inhibitors
34 27.79 ,0.001 34 29.85 ,0.001 0.556
  Angiotensin receptor blockers 9 30.22 ,0.001 3 47.67 0.019 0.099
 β -blockers 230 30.71 ,0.001 95 29.07 ,0.001 0.403
  calcium channel blockers 204 30.39 ,0.001 95 29.47 ,0.001 0.649
  Diuretics 131 29.60 ,0.001 150 30.25 ,0.001 0.741
no. of concomittant drugs
  no concomitant drugs 2659 28.27 ,0.001 908 29.36 ,0.001 0.049
  1 concomittant drug 1047 28.65 ,0.001 350 30.73 ,0.001 0.020
 $ 2 concomittant drugs 2271 28.42 ,0.001 899 29.35 ,0.001 0.113Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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were, however, nonsignificant.   During the course of the obser-
vation, 28 adverse events were reported in patients receiving 
a fixed-combination treatment (n = 28/3337; 0.8%) and 15 in 
the monotherapy treatment group (n = 15/1263; 1.2%). One 
event in each group was considered to be serious. Most adverse 
events were related to cardiac or vascular disorders. Details 
are displayed in Table 5 (MedDRA® Primary System Organ   
Classes, Northrop Grummon Corporation, California, US).
Discussion
Awareness that the majority of patients require two or 
more antihypertensive agents to reach their blood pres-
sure goal led to the therapeutic concept to introduce 
combination treatment early, which usually comprises 
a thiazide diuretic.21,22 On the other hand, clinical study 
evidence also suggests that s  ustainable inhibition of the   
renin–angiotensin–aldosterone system (RAAS) at the tis-
sue level, as provided by high-dose monotherapy with an 
ARB, might afford improved c  ardiovascular protection 
beyond pure blood pressure reduction.19 There is, however, 
no r  ecommendation on this decision to either c  ombine or 
increase dose, and reports on clinical experience from primary 
care are sparse. Th  erefore, we designed a noninterventional 
study, the key findings of which are as follows. First, the fixed-
dose combination of candesartan cilexetil 16 mg and HCTZ 
12.5 mg and high-dose monotherapy with candesartan 32 mg 
was almost equally effective at lowering blood pressure in 
patients at increased cardiovascular risk. Blood pressure 
reduction was enhanced with higher baseline blood pressure. 
Differences were small in subgroups defined by patients’ 
characteristics, risk factors, and end-organ disease. Second, 
the degree of added cardiovascular risk, as outlined by the 
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Figure 3 Systolic blood pressure reduction patient characteristic (age, gender, and BMI: two panels first row), concomitant risk factors (hyperlipidemia, waist circumference, 
smoking: two panels second row), and end-organ damage (prior cV event, gFR, and MAU: two panels last row). 
Notes: *Significant differences are indicated (P-value). Other comparisons are not significant.
Abbreviations: BMi, body mass index; CV, cardiovascular; GFR, glomerular filtration rate; HCTZ, hydrochlorothiazide; MAU, microalbuminuria.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 5 number of patients with adverse events or serious adverse events during the survey and adverse events coded by MedDRA® 
Version 11.1 (safety population: n = 4600)
Candesartan 16 mg + hydrochlorothiazide   
12.5 mg (n = 3337)
Candesartan 32 mg (n = 1263)
n % n %
no adverse events 3313 99.3 1245 98.6
Any adverse events 24 0.7 18 1.4
  serious adverse events 1 0.0 2 0.2
  not serious 23 0.7 16 0.9
MedDRA® primary system organ classes 
Adverse events 24 100 18 100
  general disorders and administration site conditions 1 4.2 1 5.6
  skin and subcutaneous tissue disorders 3 12.5 1 5.6
  Respiratory, thoracic, and mediastinal disorders 4 16.7 6 33.3
  gastrointestinal disorders  3 12.5 1 5.6
  nervous system disorders 2 8.3 1 5.6
  Vascular disorders 5 20.8 1 5.6
  cardiac disorders 4 16.7 4 22.2
  Musculoskeletal and connective tissue disorders 1 4.2 1 5.6
  investigations 1 4.2 1 5.6
Table 4 Laboratory values at baseline and during follow-up
Candesartan 16 mg +  
hydrochlorothiazide 12.5 mg
Candesartan 32 mg P-value 
∆ combination vs 
∆ monotherapy Baseline 12 weeks ∆ vs baseline Baseline 12 weeks ∆ vs baseline
Blood glucose
    Fasting blood  
glucose (mg/dL)
108.8 ± 28.9 103.2 ± 25.8   5.5 ± 18.5 110.5 ± 32.2 106.3 ± 27.5   4.19 ± 23.26 0.257
    Postprandial  
glucose (mg/dL)
147.7 ± 34.9 136.6 ± 32.1 11.1 ± 27.1 148.6 ± 40.3 136.6 ± 37.3   12.0 ± 34.9 0.717
Lipids
  Total cholesterol (mg/dL) 218.2 ± 34.6 205.0 ± 34.5 13.3 ± 29.0 220.4 ± 43.3 210.9 ± 86.7   9.4 ± 86.4 0.351
    High-density lipoprotein  
cholesterol (mg/dL) 
  51.1 ± 15.2   52.6 ± 16.1 1.50 ± 10.0   52.4 ± 16.6   53.8 ± 19.5   1.4 ± 16.8 0.883
    Low-density lipoprotein  
cholesterol (mg/dL)
131.9 ± 34.9 121.9 ± 30.2 9.95 ± 25.4 135.0 ± 43.9 122.7 ± 32.3   12.3 ± 40.6 0.296
  Triglycerides (mg/dL) 187.0 ± 92.7 168.7 ± 71.6 18.3 ± 65.8 189.1 ± 96.2 173.4 ± 112.6   15.7 ± 109.8 0.650
Renal parameters
  serum-creatinine (mg/dL)   1.55 ± 7.3   1.04 ± 1.5   0.5 ± 7.4   2.3 ± 10.3   1.1 ± 0.7   1.24 ± 10.3 0.157
    Glomerular filtration  
rate (mL/min/1.73 m2)
  71.6 ± 12.2   73.5 ± 22.7 1.90 ± 12.17   64.8 ± 21.4   67.4 ± 22.4   2.6 ± 13.9 0.664
  Albuminuria (mg/24 h)   76.5 ± 213.0   46.7 ± 87.8 30.7 ± 172.8 123.6 ± 253.1   84.2 ± 205.8 39.03 ± 133.9 0.666
safe and effective blood pressure reduction.7,24–29   Furthermore, 
there is evidence from a study published by Ohma et al that 
the ARB candesartan is more effective compared with the 
first-generation ARB losartan. The reduction in blood   pressure 
and the proportion of patients with normalized blood pressure 
were greater with the candesartan 16 mg and HCT 12.5 mg 
combination than with the losartan 50 mg and HCT 12.5 mg 
combination,30 supporting the interpretation that not all ARBs 
are similarly effective. The antihypertensive effect of cande-
sartan and HCT has been shown to be dose related over a wide 
range of doses, and the effects of the components are fully 
ESH/ESC   guidelines,21,23 was substantially reduced in both 
treatment groups. Third, tolerability was high, with 0.8% of 
patients experiencing adverse events in the fixed-combination 
and 1.2% in the high-dose monotherapy group. Fourth, 
  physicians chose to use high-dose monotherapy in patients 
with more advanced disease.
Blood pressure reduction in cHiLi  
Triple T in perspective
Clinical trials evaluating candesartan monotherapy or 
  candesartan/HCTZ combination therapy consistently show Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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additive.31 The present study comparing high-dose candesartan 
32 mg monotherapy with   candesartan and HCTZ combination 
therapy revealed similar e  ffective blood p  ressure reduction of 
both treatment regimens (Figure 1) independent of the baseline 
risk stratification (Figure 2). A higher baseline risk (which cor-
responds to a higher blood pressure at baseline) consistently 
resulted in a more pronounced blood pressure reduction of the 
respective treatment regimen. These results support the use of 
both treatment regimens for hypertensive patients, spanning the 
complete risk spectrum of hypertension-induced complications 
independent of risk at baseline.
High-dose monotherapy versus  
dual-combination treatment
Based on the results of the present study, both treatment 
regimens were similarly effective at reducing blood pres-
sure. Systolic blood pressure reduction was slightly more 
pronounced in the high-dose monotherapy group, but this 
difference disappeared when grouping patients according 
to baseline grade of hypertension (Figure 1).
The rationale for combining an ARB with HCTZ is that the 
mechanism of action is complementary and RAAS blockade 
augments the blood pressure-lowering efficacy of diuretics 
while alleviating their adverse effects. Thiazide diuretics 
lower blood pressure through natriuresis, resulting in volume 
depletion and reduction of peripheral vascular resistance over 
time.32,33 Combining an ARB with a diuretic reduces vasocon-
striction mediated by angiotensin II, at the same time reducing 
volume and enhancing the efficacy of both antihypertensive 
components. Therefore, combination therapy may help patients 
attain blood pressure control in a timelier manner. To achieve 
this, ARBs at a standard dose are usually combined with 
low-dose diuretics.34 The rationale to use high-dose ARBs is 
their proven protective effect for end-organs. Their particular 
benefit relates to their protective effect on end-organs such as 
the heart,8–11 kidneys,12–16 and brain.17,18 However, results were 
usually obtained with high doses of candesartan cilexetil, such 
as 32 mg or even higher, as applied in the SMART (Supra 
Maximal Atacand Renal Trial).34 An advantage of including a 
high-dose ARB in antihypertensive treatment is the low rate of 
adverse events associated with this class compared with other 
antihypertensive agents.35,36 Both ARB and HCTZ combination 
and ARB monotherapy have been shown to be associated with 
a low rate of treatment discontinuations.37 Taking into account 
these considerations, a further rational approach would be to 
make use of the end-organ protective effect using 32 mg of an 
ARB and combining this dose with HCTZ as outlined previ-
ously. This has been shown to be effective in clinical trials, and 
further clinical practice research is ongoing.29 We were able 
to show that younger people aged # 65 years, patients with 
dyslipidemia, smokers, patients with a prior cardiovascular 
event, and patients with microalbuminuria had improved 
blood pressure reduction in the high-dose candesartan mono-
therapy group compared with patients without the respective 
condition. Physicians were also more likely to assign high-
dose monotherapy to patients with pre-existing (vascular) 
disease. These findings are in accordance with observations 
showing that the use of an ARB reduces both proteinuria and 
the rate of deterioration of renal function beyond those seen 
with equivalent blood pressure reduction from conventional 
antihypertensive agents.12–16 In particular, proteinuria has 
been a marker of kidney disease, and recent research has 
shown that renal and cardiovascular outcomes seem to cor-
relate with the pretreatment levels of proteinuria and with 
the reduction of proteinuria with treatment.38–42 In the present 
trial, patients on candesartan experienced higher reductions in 
microalbuminuria in the candesartan high-dose arm compared 
with the candesartan and HCTZ combination treatment arm, 
although this change did not reach statistical significance. 
However, patients with prior microalbuminuria responded to 
candesartan with increased blood pressure reduction, which 
might reflect organ-protective effects of high-dose RAAS   
blockade.
Classification of cardiovascular risk and 
impact of candesartan cilexetil treatment
The ESH/ESC guidelines recommend total cardiovascular risk 
evaluation in every patient in order to refine pharmacotherapy. 
The blood pressure threshold at which to commence drug 
administration, the target blood pressure to be reached by drug 
treatment, and the decision to use two-drug combinations as 
an initial treatment step are influenced by this classification.43 
The 2009 update of this guideline now underlines that the 
presence of subclinical organ damage results in cardiovascular 
risk to be in the high range, ie, an absolute risk of at least 20 
cardiovascular events in 100 patients within 10 years.44 The 
update further expresses that there is indisputable evidence 
that major drug classes differ in their ability to protect against 
overall cardiovascular risk or cause-specific cardiovascular 
events such as stroke and myocardial infarction.44
We were able to demonstrate with this noninterventional 
study that added cardiovascular risk is substantially lowered 
with either high-dose mono- or combination therapy includ-
ing candesartan cilexetil. Although several two-drug com-
binations are suitable for clinical use, outcome trials point 
to a favorable role of combining RAAS blocking agents Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with diuretics.45 Further, there is a particular role for ARBs, 
eg, candesartan cilexetil, in patients with diabetes.44
Limitations
The present results have to be considered against the back-
ground of potential limitations. The study was not controlled, 
and therefore the role of a placebo effect or the withdrawal of 
antihypertensive agents is unknown. Second, in the absence of 
a randomization procedure, the influence of unknown biases, 
eg, through patient selection, cannot be ruled out. Thus, we 
observed more patients with higher risk and more concomi-
tant diseases in the monotherapy group. This selection clearly 
indicates that physicians preferred monotherapy in the group 
with higher risk and avoided diuretic impairment. Concomitant 
diuretic prescription could be due to a higher rate of kidney 
disease. Third, changes in concomitant medication influencing 
the metabolic profile (eg, lipid-lowering drugs, oral antidiabetic 
agents, or insulin) have not been documented in the present 
study. However, it should be kept in mind that observational 
studies in primary care, including typical patient groups and 
reflecting current treatment approaches, are useful for comple-
menting the findings of randomized controlled trials.46
Conclusion
Both the fixed-dose combination of candesartan cilexetil 
16 mg and HCTZ 12.5 mg and high-dose monotherapy with 
candesartan 32 mg are highly effective and safe for lowering 
blood pressure in patients at increased cardiovascular risk 
with mild, moderate, or severe hypertension. The choice of 
either strategy therefore largely depends on the principal aim: 
blood pressure reduction with pronounced volume restriction 
or pronounced additional end-organ protection.
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